Newsletter

Key Stock Information

Relief shares are listed on the SIX Swiss Exchange under the valor symbol RLF and quoted on the U.S. OTCQB Venture Market under the symbol RLFTF

Share details (SIX)
Valor symbol
RLF
ISIN
CH1251125998
Regulatory standard
International Reporting Standard
Trading currency
CHF
Nominal share value
CHF 4,00
Registered share capital (in shares)

14'040'837

Authorized capital band (in shares)

2'500'000

Conditional capital (in shares)
4'171'924
Auditor
Mazars
Principal shareholders
Global Emerging Markets (GEM)

    

Share details (U.S. OTCQB)
Ticker symbol

RLFTF

Trading currency

USD

    

Share details (U.S. ADR OTCQB)
Ticker symbol

RLFTY

Trading currency

USD

Disclosure of Shareholdings

Shareholders who hold shares in a company incorporated in Switzerland whose equity securities are listed in Switzerland have the duty to disclose if they reach, exceed or fall below certain thresholds (3, 5, 10, 15, 20, 25, 33 1/3, 50, 66 2/3 % of voting rights).

Please inform us in case of exceedance or shortfall of the threshold by post or e-mail (This email address is being protected from spambots. You need JavaScript enabled to view it.) with the official term, “Disclosure of Shareholdings.”

The reporting form can be found at this link:  www.ser-ag.com 

Corporate Presentation

We're refreshing our corporate presentation, coming soon!

SEC FILINGS

For all SEC filings, please click here.

ANALYST COVERAGE

valuationLAB valuationLAB report, April 10, 2023
Bob Pooler
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Analysts' opinions, estimates, or forecasts regarding Relief Therapeutics’ performance are their own and do not represent opinions or predictions of Relief Therapeutics or its management. Relief Therapeutics does not endorse or concur with the information, opinions, conclusions, or recommendations provided by analysts. Users are advised to exercise their own judgment and seek professional advice before making any investment decisions based on the information presented in the analysts' reports. Relief Therapeutics does not comment on the research coverage and disclaims any liability for the statements made or for the use of such information by third parties.

Articles of Association

    U.S. ADR Program

      Financial Calendar

      • Half-Year Report

        September 15, 2023

      • Annual General Meeting

        June 20, 2023
      • Extraordinary General Meeting

        April 28, 2023
      • Annual Report

        April 12, 2024

        Shareholder FAQS

        Relief shares are listed on the SIX Swiss Exchange and quoted on the U.S. OTCQB Venture

        Company

        What is the Company's mission?
        To provide patients with therapeutic RELIEF from serious diseases with high unmet medical need.
        When was Relief founded?
        RELIEF THERAPEUTICS Holding AG was formed in 2013 by three ex-Merck (Serono division) employees.
        How can I receive the latest corporate news releases? Where are the archived releases located?
        To receive our latest news releases, please register for our corporate newsletter. Once registered, you will receive all corporate news as soon as they are published. Archived press releases can be found here: https://relieftherapeutics.com/archive-press.
        How can I view documents Relief has filed with the SIX Swiss Exchange?

        To view all documents filed with the SIX Swiss Exchange, please visit the “Notices Market Participants” section of ser-ag.com and select RELIEF THERAPEUTICS Holding AG in the Issuer filter.

        When does Relief publish its financial results?

        We publish our half year and annual results in compliance with SIX requirements. Typically, this occurs in April and September of each fiscal year, respectively.

         

        Stock

        How is Relief’s stock traded?

        Our shares are listed on the SIX Swiss Exchange under the symbol RLF and are quoted in the U.S. on the OTCQB Market under the symbol RLFTF. Additionally, the Company has a level 1 U.S. ADR traded on the OTCQB under the symbol RLFTY.

        When did Relief go public?
        Relief was formed from a reverse merger with THERAMetrics Holding AG in 2016. THERAMetrics Holding AG (then mondoBIOTECHHolding AG) was listed on the SIX since 2009. Following the business combination, Relief took over the SIX listing.
        Is Relief's stock part of a benchmark index?

        Relief's stock is included, among others, in the Swiss Exchange Swiss Performance Index, the MSCI Global Small Cap Index, as well as the SXI Life Sciences and SXI Bio+Medtech indices.

        How many stock options and warrants are outstanding?

        As of June 30, 2023, there were 182'283 outstanding stock options under the Company's stock option plans and 1'800'000 outstanding warrants as issued in the June 2023 private placement. Each option and warrant allows its holder to acquire one share at a predetermined price.

        Does Relief pay dividends?
        The Company is not currently generating revenue; no dividends are being paid.

         

        RLF-100®

        When do you expect FDA-approvals for either the intravenous or inhaled formulations?

        We cannot speculate on the likelihood or timing of FDA approvals. In March 2021, Relief’s partner, NeuroRx, reported top-line 60-day results from the phase 2b/3 clinical trial in critical COVID-19 patients with respiratory failure. On the basis of these findings, in May 2021, NRx Pharmaceuticals, Inc. (NRx) (now the parent of NeuroRx) submitted an application to the FDA for Emergency Use Authorization (EUA), which was subsequently declined in November 2021. In January 2022, NRx announced that it had submitted an application to the FDA seeking EUA for the use of aviptadil to treat patients with critical COVID-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including remdesivir and who are ineligible for enrollment into the ACTIV-3b NIH-sponsored trial, which was subsequently denied in July 2022. 

        The U.S. phase 2/3 study with the inhaled formulation of RLF-100® was initiated by NeuroRx, Inc. in February 2021. In March 2022, NRx announced the study was paused. 

        Can you explain your partnership with NeuroRx?

        In September 2020, Relief entered into a binding collaboration agreement with NeuroRx (the “Collaboration Agreement”) which established the terms under which both parties would collaborate and assist each other to maximize the commercial value of each parties’ territories related to intravenous and inhaled aviptadil for the treatment of COVID-19 and other related pulmonary conditions. However, based on numerous breaches of the Collaboration Agreement by NeuroRx, in October 2021, Relief filed a lawsuit against NeuroRx and its then CEO, Dr. Jonathan Javitt, for multiple breaches of the Collaboration Agreement. The complaint, among other remedies, sought damages, an order compelling defendant to comply with multiple provisions of the Collaboration Agreement, and a declaration directing NeuroRx to deliver the entire data set from the Phase 2b/3 clinical trial of intravenously-administering aviptadil to Relief. On January 10, 2022, NeuroRx filed a complaint against Relief alleging that the Company is in breach of the Collaboration Agreement and has thus repudiated and cancelled the Collaboration Agreement. Additionally, NeuroRx’s claims include a count for defamation.

        On November 14, 2022, Relief and NRx announced they had entered into a definitive settlement agreement to resolve all matters relating to the pending litigation. At the closing of this settlement, held on December 19, 2022, (i) NRx transferred to Relief all of the assets that it previously used in its aviptadil development program, including its regulatory filings, patent applications, clinical data, and the formulation of the aviptadil product it was previously developing, (ii) Relief has the exclusive right and control going forward to develop and commercialize an aviptadil product, (iii) Relief has agreed to use commercially reasonable efforts to continue the existing Right to Try Program for aviptadil in the United States for at least 2 years, (iv) Relief will pay NRx milestone payments if it can successfully obtain commercial approval of an aviptadil product (whether for COVID-19 or any other indication), (v) Relief will pay NRx royalties based on a percentage of future sales of an aviptadil product (whether for COVID-19 or any other indication), up to a maximum of $30 million in the aggregate, (vi) NRx Pharmaceuticals has agreed not to compete in the development of an aviptadil product in the future, and (vii) Relief and NRx Pharmaceuticals have dismissed their pending litigation.

        What is your IP position for RLF-100™?

        Relief holds a patent covering potential formulations of RLF-100® in the United States valid until at least July 2029, with extension opportunities up to five years, as well as in the EU and Rest of World (Great Britain, Germany, Turkey, Spain, Switzerland, Netherlands, Denmark, Ireland, Austria, PRC and Mexico) valid until at least 2026, excluding extension opportunities comparable to the U.S. The acquisition of AdVita Lifescience GmbH in July 2021, enabled us to strengthen our intellectual property position with pending intellectual property rights that cover an improved formulation of the inhaled version of RLF-100® (aviptadil) and its potential application for the treatment of acute respiratory distress syndrome (“ARDS”) unrelated to COVID-19 infection, as well as in other pulmonary disorders, including sarcoidosis, berylliosis and checkpoint inhibitor-induced pneumonitis, for which AdVita has already filed pending patent claims. 

         

        OLPRUVA™ (sodium phenylbutyrate) (formerly know as ACER-001)

        What is OLPRUVA (sodium phenylbutyrate)?

        On August 14, 2023, Acer announced that OLPRUVA™ kits were commercially available in the U.S. in all dosage strengths. Acer also announced its intention to add commercial and medical affairs resources, and the introduction of its patient support service called OLPRUVA™ Navigator. Relief, in accordance with its exclusive license agreement with Acer, intends to submit a Marketing Authorization Application for approval of OLPRUVA for the treatment of UCDs in the U.K. and EU. There can be no assurance, however, that OLPRUVA will be approved for commercialization in the U.K. or the EU.

        What is the nature of your partnership with Acer Therapeutics?

        Our partnership terms and historic with Acer Therapeutics can be viewed here:
        https://relieftherapeutics.com/partnering